STRATIPHRENIA

Stratified diagnosis and new treatments for patients with schizophrenia

StratiPhrenia Ltd. is a biotech, employee-owned spin-out company of the National Institute of Mental Health (NIMH) that provides stratified diagnostics and novel treatments for patients with schizophrenia (SZ). It is built on NUDZ's groundbreaking and unique, patent-protected research. StratiPhrenia's scientific and technological breakthrough is the patent-protected discovery of 3 biologically distinct clusters of schizophrenia (SZ) patients. Within just 12 months of the first episode of the disease, each cluster of SZ patients exhibits morphologically distinct MRI (magnetic resonance imaging) profiles in the architecture of the cerebral cortex. This allows us to develop a simple and clinically applicable panel of blood biomarkers.

Unique Selling Points:

- Stratification of schizophrenia by biological subtypes in the early phase of the disease.
- Strong research background supported by expert data from the NUDZ.
- Patent-protected discovery and process.
- Potential for personalized medicine in psychiatry.

Product

A simple and clinically applicable panel of blood biomarkers

Technology readiness

Development

- Proof of concept

Prototype

First implementation

Extensive implementation

1/2024 B2B B2G

www.stratiphrenia.com